Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M

Entrada Therapeutics, Inc.

Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.
Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.
Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.
Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.
Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other corporate updates.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.